Pulmonx Corporation (NASDAQ:LUNG) Given Consensus Recommendation of “Hold” by Analysts

Pulmonx Corporation (NASDAQ:LUNG) has received an average rating of “Hold” from the seven ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $5.5833.

LUNG has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of Pulmonx from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmonx in a research note on Monday. Finally, D. Boral Capital reiterated a “buy” rating and set a $14.00 price target on shares of Pulmonx in a report on Thursday, April 30th.

Hedge Funds Weigh In On Pulmonx

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LUNG. XTX Topco Ltd bought a new stake in shares of Pulmonx in the 2nd quarter worth $149,000. Norges Bank bought a new position in shares of Pulmonx during the second quarter valued at $392,000. Jane Street Group LLC lifted its holdings in shares of Pulmonx by 3,328.7% during the second quarter. Jane Street Group LLC now owns 88,631 shares of the company’s stock valued at $230,000 after purchasing an additional 86,046 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Pulmonx by 556.6% during the second quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock valued at $1,246,000 after buying an additional 407,971 shares during the last quarter. Finally, Two Sigma Investments LP boosted its position in shares of Pulmonx by 50.3% during the third quarter. Two Sigma Investments LP now owns 46,456 shares of the company’s stock valued at $75,000 after buying an additional 15,557 shares during the last quarter. 91.04% of the stock is owned by institutional investors.

Pulmonx Trading Down 2.7%

NASDAQ LUNG opened at $1.44 on Thursday. Pulmonx has a 12 month low of $1.13 and a 12 month high of $3.88. The company has a current ratio of 4.91, a quick ratio of 4.04 and a debt-to-equity ratio of 0.81. The stock’s fifty day moving average price is $1.42 and its 200-day moving average price is $1.54. The stock has a market cap of $60.82 million, a P/E ratio of -1.11 and a beta of 0.30.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings results on Wednesday, April 29th. The company reported ($0.33) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.33). The firm had revenue of $20.59 million during the quarter, compared to analyst estimates of $20.43 million. Pulmonx had a negative return on equity of 92.94% and a negative net margin of 60.09%. As a group, equities analysts forecast that Pulmonx will post -1.13 EPS for the current fiscal year.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.